Please assess the completion status of the following clinical trial:

Trial Title: Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Fasting c-peptide below lower limit of normal fasting range~* Duration of type 1 diabetes for at least 12 months~* Current treatment: Basal - bolus regimen for at least 4 months with intermediate or long-acting insulin once, twice or three times daily as basal insulin and 3-4 premeal insulin aspart or lispro injections~* HbA1c maximum 9.0% (using Biorad Variant method)~* Able and willing to perform self-monitoring of blood glucose~* Basal insulin requirement at least 30% of the total daily insulin dose~* BMI (body Mass Index) maximum 35 kg/m\^2~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Total daily insulin dose above 1.4 IU/kg/day~* Known unawareness of hypoglycaemia~* Impaired hepatic function~* Impaired renal function~* Cardiac problems~* Uncontrolled, treated/untreated hypertension~* Known or suspected allergy to trial product or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Detemir (Type: EXPERIMENTAL): None
- NPH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).